Japan's Takara Bio to launch contract production of mRNA vaccines

TOKYO -- Takara Bio will mass produce mRNA vaccines from next year on a contract basis, Nikkei has learned, becoming one of the first Japanese companies to build key manufacturing facilities that will help cut the nation's reliance on imports.